April 3, 2025
ORLANDO, Fla. — In moderate to severe plaque psoriasis, two highly selective oral TYK2 inhibitors produced a level of response in phase 2 studies suggesting that […]
April 3, 2025
TOPLINE: Ruxolitinib cream was well tolerated, and the application of the cream led to clinically meaningful repigmentation in patients with vitiligo at 1 year, regardless of […]
April 3, 2025
TOPLINE: In a review of pregnant patients with pityriasis rosea (PR), 19% experienced unfavorable outcomes, which were higher in cases that occurred before 15 weeks gestation. […]
April 2, 2025
TOPLINE: Pembrolizumab demonstrated clinical activity in patients with mycosis fungoides (MF) and Sézary syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma (CTCL), with nearly […]
April 1, 2025
ORLANDO, Fla. — A second phase 2 trial with the tyrosine kinase 2 (TYK2) inhibitor deucravacitinib has met the primary efficacy endpoints for the treatment of […]
March 31, 2025
TOPLINE: In a survey of pediatric patients with vitiligo, only 51.4% were offered narrowband ultraviolet B (NB-UVB) phototherapy, and 45.1% received this treatment before the age […]
March 31, 2025
Older adults with severe or refractory psoriatic disease face a unique challenge: Balancing the need for effective systemic treatment with the increased risk for serious infections. […]
March 28, 2025
TOPLINE: Low-dose doxycycline showed comparable efficacy with high-dose treatment in patients with lymphocytic scarring alopecia, with a lower rate of adverse events (AEs) and related discontinuations. […]
March 28, 2025
TOPLINE: Patients with moderate to severe psoriasis treated with ustekinumab and guselkumab showed a trend towards a lower risk for herpes zoster (HZ) and postherpetic neuralgia […]